Patients with locally advanced esophageal squamous cell carcinoma achieving neoadjuvant chemoradiotherapy followed by surgery experienced a median survival of 83.9 months, significantly surpassing outcomes of those treated with chemotherapy or definitive chemoradiotherapy, which recorded 27.8 and 26.5 months respectively. Propensity-matched analysis further confirmed the survival advantage, with neoadjuvant chemoradiotherapy plus surgery yielding a median survival of 56.8 months compared to 43.1 months for definitive chemoradiotherapy. These findings suggest a crucial paradigm shift in treatment methodology.
Multicenter Study by None None in BJS Open
© The Author(s) 2025. Published by Oxford University Press on behalf of BJS Foundation Ltd.